METEOR Trial Reports on the Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals with Subclinical Atherosclerosis.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 20631478.
- Also identified by DOI 10.3810/psm.2010.06.1797.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The data from the METEOR trial show that asymptomatic low-risk patients treated with rosuvastatin have a reduction in progression of carotid intima-media thickness (CIMT) over 2 years versus placebo. ORIGINAL ARTICLE: Crouse JR 3rd, Raichlen JS, Riley WA, et al; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297(12):1344-1353.
Medical subject headings
- Atherosclerosis
- Carotid Arteries
- Fluorobenzenes
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Pyrimidines
- Sulfonamides
- Tunica Intima